|
|
| (131 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | {{Image|Noninferiority and equivalency randomized controlled trials.jpg|right|350px|Noninferiority and equivalency randomized controlled trials.}} |
| {{Sporotrichosis}} | |
| | |
| {{CMG}}; {{AE}} {{AJL}}
| |
| | |
| ==Treatment==
| |
| {|class="wikitable"| style="border: 0px; font-size: 90%; margin: 3px; width: 80%" align=center
| |
| |valign=top|
| |
| |+
| |
| ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Form}}
| |
| ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Primary Line of Treatment}}
| |
| ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Alternative Treatment}}
| |
| ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Remarks/Other}}
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Uncomplicated cutaneous
| |
| |
| |
| * [[Itraconazole]] 200 mg PO qd
| |
| |
| |
| * [[Itraconazole]] 200 mg PO bid, {{Or}}
| |
| * [[Terbinafine]] 500 mg PO bid, {{Or}}
| |
| * [[Potassium iodide|SSKI]] increasing doses, {{Or}}
| |
| * [[Fluconazole]] 400-800 mg PO qd, {{Or}}
| |
| * Local hyperthermia
| |
| |Continue treatment for 2-4 weeks after lesions resolve.
| |
| |- | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Osteoarticular | |
| |
| |
| * [[Itraconazole]] 200 mg PO bid
| |
| |
| |
| * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>'''
| |
| * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd until symptom resolution
| |
| |For a total of 12 months, switch to [[Itraconazole]] after resolution/end of treatment.
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Pulmonary
| |
| |
| |
| * Limposomal [[amphotericin B]] 3-5 mg/kg IV qd '''<u>THEN</u>'''
| |
| * [[Itraconazole]] 200 mg PO bid
| |
| |
| |
| * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>'''
| |
| * [[Itraconazole]] 200 mg PO bid upon symptom resolution
| |
| |Treat less sever cases with a 12 month regimen of [[Itraconazole]].
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Meningeal
| |
| |
| |
| * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>'''
| |
| * [[Itraconazole]] 200 mg PO bid
| |
| |
| |
| * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>'''
| |
| * [[Itraconazole]] 200 mg PO bid upon symptom resolution
| |
| |Precise length of amphotericin B treatment varies. Suppressive treatment with [[Itraconazole]] is necessary.
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Dissimated
| |
| |
| |
| * Limposomal amphotericin B 3-5 mg/kg IV qd '''<u>THEN</u>'''
| |
| * [[Itraconazole]] 200 mg PO bid.
| |
| |
| |
| * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd '''<u>THEN</u>'''
| |
| * [[Itraconazole]] 200 mg PO bid upon symptom resolution
| |
| |Continue amphotericin B treatment until patient shows marked improvement for a minimum of 12 months. Suppressive treatment with [[Itraconazole]] is necessary.
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sporotrichosis in pregnant women
| |
| | colspan="2" |
| |
| * Treat with limposomal amphotericin B 3-5 mg/kg IV qd '''<u>OR</u>'''
| |
| * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd only for severe cases of sporotrichosis '''<u>OR</u>'''
| |
| * In cases of uncomplicated cutaneous, treat with only hyperthermia.
| |
| | |
| |It is preferable to defer treatment in uncomplicated cases.
| |
| |-
| |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Sporotrichosis in Children
| |
| |
| |
| * [[Itraconazole]] 6-10 mg PO qd to a max of 400 mg PO qd for mild cases '''<u>OR</u>'''
| |
| * Deoxycholate amphotericin B 0.7-1 mg/kg IV qd for severe cases
| |
| |
| |
| * [[Potassium iodide|SSKI]] increasing doses equivalent to half the adult dose, continuing treatment for 2-4 weeks after resolution of symptoms.
| |
| |
| |
| |}
| |
| <ref name="pmid17968818">{{cite journal| author=Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America| title=Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2007 | volume= 45 | issue= 10 | pages= 1255-65 | pmid=17968818 | doi=10.1086/522765 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968818 }} </ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Disease]]
| |
| [[Category:Infectious disease]]
| |
| [[Category:Infectious Disease Project]]
| |
